We use first and third party cookies to track your browsing habits on our website in order to provide you with better quality and security, and improve the services offered through this website. If users do not explicitly confirm that they consent to the installation of cookies but continue to browse our website, we will assume that they have agreed and we will inform them accordingly about the possibility of blocking or deleting any previously installed cookies by adjusting their browser settings. You can find out more about cookies in our "Cookie Policy"

CONFIRM Cookie Policy

LIST OF CLINICAL TRIALS

Search for clinical trials open in our centers by cancer type.

PLEASE MAKE A SELECTION TO
BROWSE RESULTS

OPEN TRIAL CLOSED TRIAL

LUNG AND PLEURAL CANCER

ARIAD ALTA-1 [OPEN TRIAL]

Phase III multicenter, open label study of brigatinib (AP26113) vs. crizotinib in patients with advanced ALK-positive lung cancer. Protocol: AP26113-13-301

+ INFO

LUNG AND PLEURAL CANCER

ATALANTE1 [OPEN TRIAL]

Ramdomized, phase III clinic trial in paralel groups of OSE 2101 in second line following failure of platinum-based chemotherapy, or as third line following failure of platinum and immune control point inhibitors, compared with standard treatment (docetaxel or pemetrexed) in patients with HLA-A2 positive and metastatic or locally-advanced non-small cell lung cancer (IIIB) not eligible for radiotherapy. Protocol OSE2101C301

+ INFO

BREAST CANCER, EXPLORATORY STUDIES

AURORA PROGRAM [OPEN TRIAL]

Towards a better understanding of molecular aberrations in metastatic breast cancer. Exploratory Study.

+ INFO

LUNG AND PLEURAL CANCER

AZENT [OPEN TRIAL]

Phase IIa clinical trial of safety and efficacy of AZD9291 in treatment-naïve patients with EGFR mutated advanced non-small-cell lung cancer (NSCLC) with concommitant presence of the EGFR T790M mutation. Protocol: MedOPP112

+ INFO

LUNG AND PLEURAL CANCER

BO39694 [OPEN TRIAL]

A multicenter, international, rollover study of alectinib in patients with anaplastic lymphoma kinase (ALK)-positive or rearranged during transfection (RET)-positive cancer.

+ INFO

LUNG AND PLEURAL CANCER

BV-NSCLC-002 [OPEN TRIAL]

A Phase III, open-label, multicentre, randomised trial to establish safety and efficacy of an EGF cancer vaccine in inoperable, stage IV biomarker positive, wild type EGF-R NSCLC patients eligible toreceive standard treatment and supportive care. Protocol: BV-NSCLC-002

+ INFO

LUNG AND PLEURAL CANCER

CALLISTO [OPEN TRIAL]

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer. Protocol: 54767414LUC2001

+ INFO

LUNG AND PLEURAL CANCER

CDRB436E2406 [OPEN TRIAL]

A multi-country retrospective chart review study of patients with ALK-positive, BRAF V600-positive, and cMET-positive (ABC) non-small cell lung cancer (NSCLC).

+ INFO

LUNG AND PLEURAL CANCER

CL1-49076-003 [OPEN TRIAL]

Phase I/II study of oral S49076 in combination with gefitinib in advanced non-small-cell lung cancer patients with EGFR mutations who have progressed following treatment on EGFR tyrosine kinase inhibitor. Protocol: CL1-49076-003

+ INFO

BREAST CANCER

CORALEEN [OPEN TRIAL]

A Phase 2 Clinical Trial of multi-agent Chemotherapy or letrozole plus Ribociclib (LEE011) as neoadjuvant treatment for postmenopausal patients with Luminal B/HER2-negative breast cancer. Protocol: SOLTI-1402

+ INFO